Manufacturers Life Insurance Company, The Ngm Biopharmaceuticals Inc Transaction History

Manufacturers Life Insurance Company, The

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$2.44 - $4.53 $42,719 - $79,311	-17,508 Closed	0 $0
Q4 2022 Aug 11, 2023	BUY	$3.41 - $12.93 $3,024 - $11,468	887 Added 5.34%	17,508 $87,000
Q4 2022 Feb 13, 2023	BUY	$3.41 - $12.93 $3,024 - $11,468	887 Added 5.34%	17,508 $87,000
Q3 2022 Aug 11, 2023	SELL	$12.59 - $17.67 $4,305 - $6,043	-342 Reduced 2.02%	16,621 $217,000
Q3 2022 Nov 03, 2022	SELL	$12.59 - $17.67 $4,305 - $6,043	-342 Reduced 2.02%	16,621 $217,000
Q2 2022 Aug 11, 2023	BUY	$10.58 - $17.5 $23,984 - $39,672	2,267 Added 15.43%	16,963 $217,000
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $23,984 - $39,672	2,267 Added 15.43%	16,963 $217,000
Q1 2022 Aug 11, 2023	SELL	$13.81 - $18.6 $38,833 - $52,303	-2,812 Reduced 16.06%	14,696 $224,000
Q1 2022 May 20, 2022	SELL	$13.81 - $18.6 $43,750 - $58,924	-3,168 Reduced 17.73%	14,696 $224,000
Q4 2021 Feb 16, 2022	BUY	$17.26 - $22.02 $3,244 - $4,139	188 Added 1.06%	17,864 $316,000
Q3 2021 Nov 12, 2021	SELL	$20.15 - $26.19 $26,033 - $33,837	-1,292 Reduced 6.81%	17,676 $372,000
Q2 2021 Aug 12, 2021	BUY	$15.06 - $30.03 $50,104 - $99,909	3,327 Added 21.27%	18,968 $374,000
Q1 2021 May 03, 2021	BUY	$24.99 - $31.93 $3,073 - $3,927	123 Added 0.79%	15,641 $455,000
Q4 2020 Feb 12, 2021	BUY	$16.21 - $31.44 $7,245 - $14,053	447 Added 2.97%	15,518 $470,000
Q2 2020 Aug 10, 2020	SELL	$11.97 - $23.47 $19,116 - $37,481	-1,597 Reduced 9.58%	15,071 $295,000
Q1 2020 May 15, 2020	BUY	$10.0 - $19.51 $166,680 - $325,192	16,668 New	16,668 $206,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.